Recent news

Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.

January 20, 2022

It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent Inflamm-ageing and slow down functional decline in the elderly.

September 30, 2021

Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.
Data clearly showed that the application of Santersus’ highly selective therapeutic apheresis technology was able to remove circulating Neutrophil Extracellular Traps (NETs) in a randomised, sham-controlled study.

January 11, 2021

First patients is enrolled to First In-Human Clinical Trial of NucleoCapture®

December 2, 2021

Ethics Committees of two major clinics approved NucleoCapture to proceed with a clinical trial in Sepsic Patients

November 26, 2021

Santersus’ Shareholders Elect New Board Members

September 22, 2021

Santersus AG Confirms Attendance at BioTech Gate

September 1, 2021

Santersus Raises CHF 750 thousand in Family & Friends Round

1 2 3 >